• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Obeticholic acid associated with improved PBC biomarker trends compared to ursodiol: The POISE trial

byMatthew Lin, MDandShaidah Deghan, MSc. MD
August 18, 2016
in Gastroenterology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Obeticholic acid therapy in patients with primary biliary cholangitis (PBC) associated with significantly greater decreases in alkaline phosphatase (ALP) and total bilirubin over 12 month period compared to placebo.

2. Higher rates of pruritis and subsequent discontinuation in patients treated with obeticholic acid compared to placebo. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: PBC is an autoimmune disorder of the intralobular bile ducts that, even with ursodiol therapy, can eventually lead to cirrhosis and liver failure. Higher levels of ALP and bilirubin levels tend to correlate with worsening disease state. While ursodiol, the only approved treatment for PBC, can decrease hepatic biomarkers and delay time to transplantation by binding to the farnesoid X receptor (FXR) to inhibit bile acid production and stimulate choleresis, ALP levels often remain elevated. In contrast, obeticholic acid has an approximately 100x greater affinity for FXR. In this 12 month double-blind, placebo controlled phase 3 clinical trial, researchers evaluated the effects of obeticholic acid compared to placebo (both in the context of ursodiol baseline treatment for all groups) on levels of biomarkers for PBC. In general, researchers found that obeticholic acid significantly reduced ALP levels, total bilirubin levels and other markers of cholestasis (i.e. CRP, TNF-alpha, and cytokeratin 18) compared to placebo.

Click to read the study, published today in NEJM

Relevant Reading: Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study

In-Depth [randomized controlled trial]: In this study, 216 patients who were 18 years or older with a diagnosis of PBC were randomly assigned to receive either 10 mg of obeticholic acid (10 mg group, n = 73) or 5 mg initially with titration up to 10 mg (5-10 mg group, n = 71) if no adverse events occurred or primary composite end point was not met, and placebo (n = 73). All groups received standard of care ursodiol therapy. The primary composite end point was an alkaline phosphatase level <1.67x the upper limit of normal with a reduction of at least 15% from baseline, and a total bilirubin less than or equal to the upper limit of normal. Overall, the primary end point was observed in significantly higher percentage of the 5-10 mg group and 10 mg group compared to the placebo group (46% and 47% vs. 10%, respective; p < 0.001 for both comparisons). Additionally, the rate of response at study interval points was significantly greater in the 5-10 mg and 10 mg group compared to placebo, as early as 2 weeks. In terms of individual components of the primary composite end point, the treatment groups also occurred at significantly higher rates of success compared to placebo. In terms of adverse effects, pruritis was more common in the obeticholic group with higher discontinuation rates, with 56% (10% discontinued) in the 5-10 mg group, 68% (1% discontinued) in the 10 mg group compared to 38% (0% discontinued) in the placebo group.

Image: CC/Wiki

RELATED REPORTS

Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency

The Child-Pugh score: Prognosis in chronic liver disease and cirrhosis [Classics Series]

Evaluation of early vs standard liver transplant for alcohol-associated liver disease

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cirrhosis
Previous Post

Abaloparatide protects against vertebral fractures in post-menopausal osteoporotic women

Next Post

2 Minute Medicine Rewind August 15, 2016

RelatedReports

Novel combination therapy may be effective for noncirrhotic HCV infection [UNITY-1 trial]
Chronic Disease

Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency

June 29, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
General Medicine Classics

The Child-Pugh score: Prognosis in chronic liver disease and cirrhosis [Classics Series]

December 3, 2021
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Gastroenterology

Evaluation of early vs standard liver transplant for alcohol-associated liver disease

August 20, 2021
#VisualAbstract: Targeted indoor residual spraying (IRS) is non-inferior to standard IRS for malaria control in low-transmission settings
StudyGraphics

#VisualAbstract: Increased albumin infusions did not improve decompensated cirrhosis

March 17, 2021
Next Post
Use of injectable contraceptive, Depo-Provera, linked to increased risk of HIV

2 Minute Medicine Rewind August 15, 2016

Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia

Non-invasive bladder stimulation effective to obtain urine samples in infants

Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The HOT trial: Diastolic blood pressure targets in hypertension [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.